
Maravai LifeSciences Holdings, Inc. – NASDAQ:MRVI
Maravai LifeSciences Holdings stock price today
Maravai LifeSciences Holdings stock price monthly change
Maravai LifeSciences Holdings stock price quarterly change
Maravai LifeSciences Holdings stock price yearly change
Maravai LifeSciences Holdings key metrics
Market Cap | 741.84M |
Enterprise value | 1.75B |
P/E | 8.11 |
EV/Sales | 1.99 |
EV/EBITDA | 5.17 |
Price/Sales | 2.04 |
Price/Book | 3.30 |
PEG ratio | 1.61 |
EPS | -0.98 |
Revenue | 274.09M |
EBITDA | -4.60M |
Income | -131.04M |
Revenue Q/Q | -18.78% |
Revenue Y/Y | -61.81% |
Profit margin | 24.94% |
Oper. margin | 64.15% |
Gross margin | 80.87% |
EBIT margin | 64.15% |
EBITDA margin | -1.68% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMaravai LifeSciences Holdings stock price history
Maravai LifeSciences Holdings stock forecast
Maravai LifeSciences Holdings financial statements
Jun 2023 | 68.91M | -6.54M | -9.49% |
---|---|---|---|
Sep 2023 | 66.86M | -6.46M | -9.66% |
Dec 2023 | 74.14M | -105.95M | -142.92% |
Mar 2024 | 64.17M | -12.07M | -18.82% |
Sep 2025 | 73.55M | 896.56K | 1.22% |
---|---|---|---|
Oct 2025 | 74.64M | 1.35M | 1.82% |
Dec 2025 | 78.10M | 2.55M | 3.27% |
Mar 2026 | 78.04M | 810.01K | 1.04% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 2264437000 | 1.36B | 60.36% |
---|---|---|---|
Sep 2023 | 2267553000 | 1.37B | 60.65% |
Dec 2023 | 1487450000 | 697.56M | 46.9% |
Mar 2024 | 1444641000 | 667.25M | 46.19% |
Jun 2023 | 19.19M | -24.15M | -43.13M |
---|---|---|---|
Sep 2023 | 14.16M | -15.52M | 783K |
Dec 2023 | 7.79M | -12.90M | 470K |
Mar 2024 | -8.46M | -4.24M | -560K |
Maravai LifeSciences Holdings alternative data
Aug 2023 | 650 |
---|---|
Sep 2023 | 660 |
Oct 2023 | 660 |
Nov 2023 | 660 |
Dec 2023 | 670 |
Jan 2024 | 670 |
Feb 2024 | 670 |
Apr 2024 | 650 |
May 2024 | 650 |
Jun 2024 | 570 |
Jul 2024 | 570 |
Maravai LifeSciences Holdings other data
Period | Buy | Sel |
---|---|---|
May 2024 | 0 | 9940974 |
Nov 2024 | 192500 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | DEFORD JOHN A director | Class A Common Stock | 17,500 | $5.75 | $100,625 | ||
Purchase | HULL CARL director, officer.. | Class A Common Stock | 175,000 | $5.64 | $987,000 | ||
Sale | GTCR INVESTMENT XI LLC director, 10 percent owner: | Class A common stock | 9,940,974 | $9.82 | $97,570,660 | ||
Purchase | HULL CARL | Class A Common Stock | 35,000 | N/A | N/A | ||
Purchase | ORESHACK KURT | Class A Common Stock | 7,500 | $27 | $202,500 | ||
Purchase | HOPFIELD JESSICA | Class A Common Stock | 50,000 | N/A | N/A | ||
Purchase | LUCIER GREGORY T | Class A Common Stock | 15,000 | $27 | $405,000 | ||
Purchase | PRAHALAD MURALI | Class A Common Stock | 18,000 | N/A | N/A | ||
Purchase | HANCE ROBERT B | Class A Common Stock | 10,000 | N/A | N/A | ||
Purchase | SELLERS LISA | Class A Common Stock | 18,888 | $27 | $509,976 |
Quarter | Transcript |
---|---|
Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 23 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Maravai LifeSciences Holdings stock today?
One share of Maravai LifeSciences Holdings stock can currently be purchased for approximately $2.51.
-
When is Maravai LifeSciences Holdings's next earnings date?
Unfortunately, Maravai LifeSciences Holdings's (MRVI) next earnings date is currently unknown.
-
Does Maravai LifeSciences Holdings pay dividends?
No, Maravai LifeSciences Holdings does not pay dividends.
-
How much money does Maravai LifeSciences Holdings make?
Maravai LifeSciences Holdings has a market capitalization of 741.84M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.28% to 288.95M US dollars.
-
What is Maravai LifeSciences Holdings's stock symbol?
Maravai LifeSciences Holdings, Inc. is traded on the NASDAQ under the ticker symbol "MRVI".
-
What is Maravai LifeSciences Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Maravai LifeSciences Holdings?
Shares of Maravai LifeSciences Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Maravai LifeSciences Holdings's key executives?
Maravai LifeSciences Holdings's management team includes the following people:
- Mr. Carl W. Hull Co-Founder, Chairman & Chief Executive Officer(age: 66, pay: $1,250,000)
- Mr. Brian Neel Chief Operating Officer of Nucleic Acid Production(age: 49, pay: $987,100)
-
Is Maravai LifeSciences Holdings founder-led company?
Yes, Maravai LifeSciences Holdings is a company led by its founder Mr. Carl W. Hull.
-
How many employees does Maravai LifeSciences Holdings have?
As Jul 2024, Maravai LifeSciences Holdings employs 570 workers, which is 12% less then previous quarter.
-
When Maravai LifeSciences Holdings went public?
Maravai LifeSciences Holdings, Inc. is publicly traded company for more then 4 years since IPO on 20 Nov 2020.
-
What is Maravai LifeSciences Holdings's official website?
The official website for Maravai LifeSciences Holdings is maravai.com.
-
Where are Maravai LifeSciences Holdings's headquarters?
Maravai LifeSciences Holdings is headquartered at 10770 Wateridge Circle, San Diego, CA.
-
How can i contact Maravai LifeSciences Holdings?
Maravai LifeSciences Holdings's mailing address is 10770 Wateridge Circle, San Diego, CA and company can be reached via phone at 858 546 0004.
Maravai LifeSciences Holdings company profile:

Maravai LifeSciences Holdings, Inc.
maravai.comNASDAQ
580
Biotechnology
Healthcare
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0001823239
ISIN: US56600D1072
CUSIP: 56600D107